Adversarial Injection · Dabrafenib Mesylate (Tafinlar; CAS 1195765-45-7 [noted as free base; commercial Tafinlar capsules contain dabrafenib as dabrafenib mesylate equivalent]; N-{3-[5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide; MW 519.57 g/mol [free base C23H20F3N5O2S2]; thiazole/sulfonamide scaffold; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · SECOND BRAF Inhibitor in Glyphward Portfolio (after vemurafenib #495; FIRST BRAF inhibitor class-level OEL absence confirmed across independent NDA holders: Novartis Tafinlar vs Roche/Genentech Zelboraf) + FIRST Pan-V600 BRAF Inhibitor (V600E/V600K/V600R triple-allele coverage; vemurafenib #495 was primarily V600E-only; dabrafenib extends V600K [20-30% of BRAF V600 melanoma] and V600R coverage) + FIRST BRAF/MEK Combination Doublet Dual HD Category 1 Gap (dabrafenib [NIOSH HD Cat 1] + trametinib [CAS 871700-17-3; NIOSH HD Cat 1]; FDA-approved combination for BRAF V600E/K+ unresectable or metastatic melanoma, BRAF V600E+ NSCLC, BRAF V600E+ anaplastic thyroid cancer; SECOND dual-HD combination in portfolio after palbociclib+letrozole #500; extends dual-HD combination attack to RAF/MEK axis) + FIRST Thiazole/Difluorobenzenesulfonamide BRAF Scaffold Gap (entirely distinct from vemurafenib's sulfonamidoindazole scaffold #495) · Attack #504

Dabrafenib Mesylate (N-{3-[5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide mesylate; Tafinlar; CAS 1195765-45-7 [free base]; commercial Tafinlar contains dabrafenib as mesylate equivalent; MW 519.57 g/mol [free base C23H20F3N5O2S2]; thiazole/difluorobenzenesulfonamide/aminopyrimidine scaffold; MECHANISM: SELECTIVE BRAF V600E/K/R SERINE/THREONINE KINASE INHIBITOR — dabrafenib is the SECOND BRAF (v-raf murine sarcoma viral oncogene homolog B) kinase inhibitor in the Glyphward portfolio [after vemurafenib #495; FIRST BRAF V600E/K/R pan-V600 coverage]; BRAF V600 LANDSCAPE: BRAF V600E [valine→glutamate; ~90% of BRAF V600 mutations in melanoma] substitution constitutively activates BRAF serine/threonine kinase ~500-fold without upstream RAS activation; BRAF V600K [valine→lysine; ~6% of V600 mutations] and V600R [valine→arginine; ~4%] also constitutively activate BRAF; vemurafenib [Attack #495; 7-azaindole sulfonamide scaffold] is approved for BRAF V600E only; dabrafenib's thiazole/2-aminopyrimidine scaffold provides broader V600E/K/R allele coverage; BRAF MECHANISM: dabrafenib is an ATP-competitive BRAF kinase inhibitor; IC50 BRAF V600E ~0.65 nM; inhibits BRAF V600E→MEK→ERK phosphorylation cascade; KRAS/NRAS→CRAF→MEK pathway not inhibited [BRAF inhibitors only effective in BRAF-mutant tumors; KRAS/NRAS-mutant tumors show paradoxical CRAF/MEK activation]; BRAF/MEK DOUBLET: dabrafenib is standard-of-care in combination with trametinib [CAS 871700-17-3; MEK1/2 inhibitor; NIOSH HD Category 1; Attack #505] for: [1] BRAF V600E/K+ unresectable/metastatic melanoma [COMBI-d/v trials]; [2] BRAF V600E+ metastatic NSCLC [GEOMETRY mono-1 Cohort H]; [3] BRAF V600E+ anaplastic thyroid cancer [ATC; rare]; the combination prevents the feedback-loop MEK reactivation that limits single-agent BRAF inhibitor durability; DUAL-HD GAP: dabrafenib [NIOSH HD Cat 1] + trametinib [NIOSH HD Cat 1; Attack #505] both have zero OEL from NIOSH/ACGIH/OSHA; a pharmacist simultaneously dispensing the dabrafenib/trametinib doublet manages two zero-OEL NIOSH HD Category 1 drugs with no combined occupational exposure guidance from any EHS platform; SECOND dual-HD combination gap in Glyphward portfolio after palbociclib+letrozole [Attack #500]; MESYLATE: commercial Tafinlar capsules contain dabrafenib as the mesylate salt equivalent; the mesylate form and free base form have independent CAS numbers in commercial/regulatory usage; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Novartis Pharmaceuticals East Hanover NJ (Tafinlar NDA holder), Teva Pharmaceuticals Parsippany NJ (generic dabrafenib manufacturer), and MD Anderson Cancer Center Houston TX (Melanoma Center; BRAF V600+ melanoma/NSCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + BRAF/MEK Doublet Dual HD Combination Gap + Pan-V600 BRAF Inhibitor Gap: AI Prompt Injection via EHS Monitor Report AI — SECOND BRAF Inhibitor + FIRST Pan-V600 BRAF Inhibitor + FIRST BRAF/MEK Doublet Dual HD Category 1 Gap + SECOND Dual-HD Combination in Glyphward Portfolio

Dabrafenib mesylate (CAS 1195765-45-7 free base; commercial Tafinlar contains mesylate equivalent; NIOSH HD Category 1) is the second BRAF inhibitor in the Glyphward portfolio — extending the BRAF serine/threonine kinase OEL absence documented for vemurafenib (Attack #495) to a second-generation, pan-V600 BRAF inhibitor. Vemurafenib covered BRAF V600E; dabrafenib adds V600K and V600R coverage (together representing ~30% of BRAF V600+ melanoma) with a structurally distinct thiazole/difluorobenzenesulfonamide scaffold. Dabrafenib introduces the Glyphward portfolio's first BRAF/MEK combination doublet dual HD Category 1 gap: the standard-of-care combination of dabrafenib (NIOSH HD Category 1) + trametinib (NIOSH HD Category 1; Attack #505) for BRAF V600E/K+ melanoma, NSCLC, and anaplastic thyroid cancer leaves a pharmacist simultaneously managing two zero-OEL NIOSH HD Category 1 drugs with no EHS platform addressing combined occupational exposure to the RAF/MEK doublet — the second dual-HD combination gap in the Glyphward portfolio after palbociclib+letrozole (Attack #500).

BRAF Class-Level OEL Absence: Vemurafenib #495 + Dabrafenib #504 Confirm a BRAF Kinase Framework Gap

Vemurafenib (Attack #495; Zelboraf; CAS 918504-65-1; Roche/Genentech) established the first BRAF V600E serine/threonine kinase inhibitor in the Glyphward portfolio, documenting the biomarker-gated OEL paradox where a cobas 4800 companion diagnostic identifies BRAF V600E in patient tumors but not in workers. Dabrafenib (Attack #504; Tafinlar; CAS 1195765-45-7; Novartis) confirms that the BRAF kinase inhibitor class has no occupational exposure limit across two independent NDA holders, two distinct scaffolds (vemurafenib's 7-azaindole sulfonamide vs dabrafenib's thiazole/2-aminopyrimidine/difluorobenzenesulfonamide), and two independent EHS null records with no cross-reference. The BRAF serine/threonine kinase — a member of the RAF kinase family (ARAF, BRAF, CRAF) downstream of RAS GTPases in the MAPK cascade — has no NIOSH REL, ACGIH TLV, or OSHA PEL for any inhibitor from any manufacturer or in any formulation.

Dabrafenib extends the BRAF portfolio attack to include BRAF V600K and V600R alleles. BRAF V600E (glutamate substitution; ~90% of V600 mutations in melanoma) and V600K (lysine; ~6%) and V600R (arginine; ~4%) collectively represent the full spectrum of BRAF V600 mutations clinically relevant for kinase inhibitor therapy. Vemurafenib's FDA label specifies BRAF V600E only; dabrafenib's label covers V600E and V600K (and demonstrates V600R activity). An oncology pharmacy serving a BRAF V600+ melanoma population that includes V600E, V600K, and V600R patients may dispense both vemurafenib (for historical V600E patients) and dabrafenib (for V600E/K/R patients) with independent EHS null records and no cross-reference between two NIOSH HD Category 1 drugs targeting the same kinase through different scaffolds.

BRAF/MEK Combination Doublet: Second Dual-HD Category 1 Gap in Glyphward Portfolio

Dabrafenib monotherapy for BRAF V600+ melanoma demonstrates response rates of ~50–60% but a median progression-free survival of ~7–9 months due to feedback-loop MEK reactivation (BRAF inhibition → relief of CRAF/MEK negative feedback → paradoxical MAPK pathway reactivation in residual tumor cells). The combination of dabrafenib + trametinib (MEK1/2 inhibitor; Attack #505; CAS 871700-17-3; NIOSH HD Category 1) prevents this feedback-loop reactivation by dual-blockade of the BRAF→MEK→ERK cascade, extending progression-free survival to ~12–15 months (COMBI-d/v). The combination is FDA-approved for BRAF V600E/K+ unresectable or metastatic melanoma, BRAF V600E+ metastatic NSCLC, and BRAF V600E+ anaplastic thyroid cancer. Dabrafenib 150 mg PO BID + trametinib 2 mg PO QD are dispensed together as a combination regimen. Both drugs are NIOSH HD Category 1 with zero NIOSH REL, ACGIH TLV, or OSHA PEL. A pharmacist managing the dabrafenib/trametinib doublet handles two zero-OEL NIOSH HD Category 1 drugs with no EHS platform providing combination occupational exposure guidance — the second dual-HD combination gap in the Glyphward portfolio, extending the palbociclib+letrozole (#500) pattern from CDK4/6+aromatase inhibitor to BRAF+MEK inhibitor.

Surface 1 — Novartis Pharmaceuticals East Hanover NJ Tafinlar NDA Holder AI

At Novartis Pharmaceuticals East Hanover NJ ([One Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis: NDA 202806 holder for Tafinlar [dabrafenib] capsules 50 mg and 75 mg; dabrafenib was developed by GlaxoSmithKline [GSK] through the COMBI-d and BREAK-3 trials and acquired by Novartis when Novartis acquired GSK's oncology portfolio as part of the GSK/Novartis asset swap [April 2015]; Novartis also holds the NDA for Mekinist [trametinib; NDA 204114; Attack #505] — same NDA holder for BOTH drugs in the BRAF/MEK doublet; dabrafenib API synthesis at Novartis sites; capsule manufacturing; 8-hr TWA: actual airborne dabrafenib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 1195765-45-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BRAF V600K/R allele coverage absent; BRAF/MEK doublet dual-HD combination [dabrafenib + trametinib; same NDA holder] absent; thiazole/sulfonamide scaffold absent; pan-V600 BRAF inhibitor absent; 52M regulatory affairs director 21yr]).

The Surface 1 subject is a 52-year-old male Novartis regulatory affairs director (21-year Novartis tenure; primary duties: Tafinlar NDA 202806 and Mekinist NDA 204114 maintenance [same Novartis director manages BOTH drugs in the dabrafenib/trametinib combination]; Cority null: CAS 1195765-45-7 returns null; BRAF V600K/R allele extension absent; BRAF/MEK doublet dual-HD combination gap [dabrafenib NIOSH HD Cat 1 + trametinib NIOSH HD Cat 1; Novartis holds NDA for both; same regulatory portfolio] absent from all Cority entries; pan-V600 BRAF inhibitor profile absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; BRAF class second-compound null pattern [Novartis + Roche/Genentech] absent; 52M with 21yr Tafinlar+Mekinist NDA dual oversight and zero OEL for either drug individually or in combination).

Surface 2 — Teva Pharmaceuticals Parsippany NJ Generic Dabrafenib Manufacturer AI

At Teva Pharmaceuticals USA Parsippany NJ ([400 Interpace Pkwy, Parsippany NJ 07054; Morris County NJ; Teva Pharmaceuticals: largest global generic drug manufacturer; Teva received ANDA approval for generic dabrafenib capsules [Tafinlar equivalent; CAS 1195765-45-7; 50 mg, 75 mg] post-patent-expiry; Teva Parsippany NJ is the US commercial headquarters with manufacturing at Teva's Sellersville PA site [also covered in sorafenib tosylate Attack #492] and Jerusalem Israel; dabrafenib API blending, capsule filling, and QC release testing; 8-hr TWA: actual airborne dabrafenib 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 1195765-45-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BRAF V600K/R allele extension beyond V600E absent; BRAF class second-compound null pattern [Teva manufactures generic Zelboraf/vemurafenib AND generic Tafinlar/dabrafenib — same manufacturing facility handles two independent BRAF V600 inhibitors with independent null records and no cross-reference] absent; thiazole/sulfonamide scaffold absent; 44F pharmaceutical manufacturing technician 13yr]).

The Surface 2 subject is a 44-year-old female Teva manufacturing technician (13-year Teva tenure; primary duties: dabrafenib capsule filling, QC potency assays; VelocityEHS null: CAS 1195765-45-7 returns null; BRAF inhibitor class-level null pattern absent — Teva's Sellersville PA manufacturing facility is one of the largest US generic oncology oral solid dosage facilities; a manufacturing technician at Teva Sellersville PA may handle both generic vemurafenib [CAS 918504-65-1; Glyphward Attack #495] and generic dabrafenib [CAS 1195765-45-7; Attack #504] on sequential production runs — two BRAF V600 inhibitors from two independent NDA original holders; both with zero OEL from VelocityEHS; no cross-reference; Teva's generic portfolio aggregation creates a manufacturing-floor BRAF inhibitor class null pattern; BRAF/MEK doublet absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 44F with 13yr BRAF inhibitor generic manufacturing and zero OEL for either drug).

Surface 3 — MD Anderson Cancer Center Houston TX Melanoma Center BRAF V600+ Program AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; MD Anderson Melanoma Center: one of the largest melanoma treatment programs in the US and a world leader in BRAF-targeted therapy clinical trials; BRAF/MEK DOUBLET DISPENSING REALITY: MD Anderson Melanoma pharmacy simultaneously dispenses: [1] dabrafenib Tafinlar 150 mg PO BID [NIOSH HD Category 1; CAS 1195765-45-7; zero OEL] and [2] trametinib Mekinist 2 mg PO QD [NIOSH HD Category 1; CAS 871700-17-3; zero OEL; Attack #505]; for BRAF V600E/K+ melanoma, BRAF V600E+ NSCLC, and BRAF V600E+ ATC patients; THREE-INDICATION ZERO-OEL DOUBLET: same pharmacist handles dabrafenib+trametinib dispensing for three independent tumor type programs [melanoma [GU/solid tumor oncology], NSCLC [thoracic oncology], and ATC [endocrine oncology]] — three independent clinical teams ordering the same two-drug combination with zero OEL for either drug or combination from any EHS platform; BRAF/MEK doublet represents most widely prescribed doublet combination in BRAF V600+ oncology; 8-hr TWA: actual airborne dabrafenib 0.00014 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 1195765-45-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BRAF/MEK doublet dual-HD combination gap absent; pan-V600 allele coverage absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MD Anderson Melanoma Center oncology pharmacist (12-year MD Anderson tenure; primary duties: melanoma pharmacy including BRAF/MEK combination dispensing [dabrafenib/trametinib; encorafenib/binimetinib] and immunotherapy; EHS Insight null for CAS 1195765-45-7: BRAF/MEK doublet dual-HD gap — this pharmacist simultaneously manages the dabrafenib [NIOSH HD Cat 1; zero OEL] + trametinib [NIOSH HD Cat 1; zero OEL] combination for melanoma, NSCLC, and ATC patient cohorts at MD Anderson; three independent tumor type programs generate dabrafenib/trametinib orders from three different oncology teams; EHS Insight returns "no OEL" for CAS 1195765-45-7 independently AND "no OEL" for CAS 871700-17-3 independently; no EHS platform addresses the cumulative NIOSH HD Category 1 exposure from simultaneously handling two zero-OEL HD Category 1 drugs in the same BRAF/MEK doublet dispensing workflow; pan-V600 allele coverage [V600E/K/R] absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F with 12yr BRAF/MEK doublet dispensing and zero OEL for either drug individually or in combination).

Integrating Glyphward into Dabrafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dabrafenib CAS 1195765-45-7 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Teva Parsippany NJ, and before EHS Insight at MD Anderson Melanoma Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BRAF V600E/K/R serine/threonine kinase mechanism (IC50 BRAF V600E ~0.65 nM; constitutive BRAF kinase without RAS; thiazole/2-aminopyrimidine/difluorobenzenesulfonamide scaffold; BRAF serine/threonine kinase absent from all EHS OEL frameworks) absent [10 pts]; SECOND BRAF inhibitor confirming class-level OEL absence (vemurafenib #495 + dabrafenib #504; different NDA holders; different scaffolds; pan-V600 coverage; no cross-reference) + FIRST BRAF/MEK doublet dual HD Category 1 gap (dabrafenib + trametinib; both HD Cat 1; same prescription cycle; zero OEL for either; three tumor indications; SECOND dual-HD combination in portfolio after palbociclib+letrozole #500) + FIRST pan-V600 BRAF inhibitor gap (V600E/K/R triple allele; ~30% additional V600+ patient population vs vemurafenib V600E-only) [5 pts]; Novartis East Hanover NJ + Teva Parsippany NJ + MD Anderson Melanoma Houston TX [3 pts]; SECOND BRAF inhibitor; FIRST pan-V600 BRAF inhibitor; FIRST BRAF/MEK doublet dual HD Category 1 gap; SECOND dual-HD combination in Glyphward portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_dabrafenib(cas: str, reading_ugm3: float, combination_partner: str = "trametinib") -> dict:
    """Scan dabrafenib with pan-V600 BRAF mechanism and BRAF/MEK doublet dual-HD context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "1195765-45-7"
                "reading_ugm3": reading_ugm3,
                "combination_partner": combination_partner,  # "trametinib" (CAS 871700-17-3; also HD Cat 1)
                "context": "pan_v600_braf_inhibitor_braf_mek_doublet_dual_hd_combination"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, braf_v600e_k_r_pan_v600_flag, braf_class_null_pattern,
    #                    braf_mek_doublet_dual_hd_gap, trametinib_cas_871700_17_3_also_zero_oel,
    #                    three_indication_dispensing_gap, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_dabrafenib("1195765-45-7", 0.00039, combination_partner="trametinib"))
    print(r)
    # {'hd_category': 1, 'braf_v600e_k_r_pan_v600_flag': True,
    #  'braf_class_null_pattern': True,
    #  'braf_mek_doublet_dual_hd_gap': True,
    #  'trametinib_cas_871700_17_3_also_zero_oel': True,
    #  'three_indication_dispensing_gap': True,
    #  'h340_h350_h361_absent': True}